BACKGROUND: Tumor models resistant to EGFR tyrosine kinase inhibitors or cisplatin express higher levels of the immune checkpoint molecule PD-L1. We sought to determine whether PD-L1 expression is elevated in head and neck squamous cell carcinoma (HNSCC) models of acquired cetuximab resistance and whether the expression is regulated by bromodomain and extraterminal domain (BET) proteins. METHODS: Expression of PD-L1 was assessed in HNSCC cell line models of acquired cetuximab resistance. Proteolysis targeting chimera (PROTAC)- and RNAi-mediated targeting were used to assess the role of BET proteins. RESULTS: Cetuximab-resistant HNSCC cells expressed elevated PD-L1 compared to cetuximab-sensitive controls. Treatment with the BET inhibitor JQ1, the BET PROTAC MZ1, or RNAi-mediated knockdown of BRD2 decreased PD-L1 expression. Knockdown of BRD2 also reduced the elevated levels of PD-L1 seen in a model of acquired cisplatin resistance. CONCLUSIONS: PD-L1 is significantly elevated in HNSCC models of acquired cetuximab and cisplatin resistance where BRD2 is the primary regulator.
BACKGROUND: Tumor models resistant to EGFR tyrosine kinase inhibitors or cisplatin express higher levels of the immune checkpoint molecule PD-L1. We sought to determine whether PD-L1 expression is elevated in head and neck squamous cell carcinoma (HNSCC) models of acquired cetuximab resistance and whether the expression is regulated by bromodomain and extraterminal domain (BET) proteins. METHODS: Expression of PD-L1 was assessed in HNSCC cell line models of acquired cetuximab resistance. Proteolysis targeting chimera (PROTAC)- and RNAi-mediated targeting were used to assess the role of BET proteins. RESULTS: Cetuximab-resistant HNSCC cells expressed elevated PD-L1 compared to cetuximab-sensitive controls. Treatment with the BET inhibitor JQ1, the BET PROTAC MZ1, or RNAi-mediated knockdown of BRD2 decreased PD-L1 expression. Knockdown of BRD2 also reduced the elevated levels of PD-L1 seen in a model of acquired cisplatin resistance. CONCLUSIONS: PD-L1 is significantly elevated in HNSCC models of acquired cetuximab and cisplatin resistance where BRD2 is the primary regulator.
Authors: Hyun-Bae Jie; Raghvendra M Srivastava; Athanassios Argiris; Julie E Bauman; Lawrence P Kane; Robert L Ferris Journal: Cancer Immunol Res Date: 2017-04-13 Impact factor: 11.151
Authors: Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino Journal: J Clin Invest Date: 2018-09-10 Impact factor: 14.808
Authors: Adam Thompson-Harvey; Mahi Yetukuri; Alec R Hansen; Matthew C Simpson; Eric Adjei Boakye; Mark A Varvares; Nosayaba Osazuwa-Peters Journal: Cancer Date: 2019-11-13 Impact factor: 6.860
Authors: Genevieve Stein-O'Brien; Luciane T Kagohara; Sijia Li; Manjusha Thakar; Ruchira Ranaweera; Hiroyuki Ozawa; Haixia Cheng; Michael Considine; Sandra Schmitz; Alexander V Favorov; Ludmila V Danilova; Joseph A Califano; Evgeny Izumchenko; Daria A Gaykalova; Christine H Chung; Elana J Fertig Journal: Genome Med Date: 2018-05-23 Impact factor: 11.117
Authors: Silvia Pesce; Marco Greppi; Francesco Grossi; Genny Del Zotto; Lorenzo Moretta; Simona Sivori; Carlo Genova; Emanuela Marcenaro Journal: Front Immunol Date: 2019-06-04 Impact factor: 7.561
Authors: Nicholas J Skertich; Fei Chu; Imad A M Tarhoni; Stephen Szajek; Jeffrey A Borgia; Mary Beth Madonna Journal: Cancers (Basel) Date: 2022-01-31 Impact factor: 6.639